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Background: Reduced estimated glomerular filtration rate (eGFR) and albuminuria have been associated
with worse cognitive performance. However, few studies have examined whether these associations are
confined to older individuals or may be extended to the middle-aged population.
Study Design: Cross-sectional analyses of a prospective population-based cohort study.
Setting & Participants: 2,987 individuals aged 40 to 75 years from the general population (The Maastricht
Study).
Predictor: eGFR and urinary albumin excretion (UAE).
Outcomes: Memory function, information processing speed, and executive function.
Measurements: Analyses were adjusted for demographic variables (age, sex, and educational level),
lifestyle factors (smoking behavior and alcohol consumption), depression, and cardiovascular disease risk
factors (glucose metabolism status, waist circumference, total to high-density lipoprotein cholesterol ratio,
triglyceride level, use of lipid-modifying medication, systolic blood pressure, use of antihypertensive
medication, and prevalent cardiovascular disease).
Results: UAE was ,15 mg/24 h in 2,439 (81.7%) participants, 15 to ,30 mg/24 h in 309 (10.3%),
and $30 mg/24 h in 239 (8.0%). In the entire study population, UAE $ 30 mg/24 h was associated with lower
information processing speed as compared to UAE , 15 mg/24 h (b [SD difference] 5 20.148; 95%
CI, 20.263 to 20.033) after full adjustment, whereas continuous albuminuria was not. However, significant
interaction terms (P for interaction , 0.05) suggested that albuminuria was most strongly and extensively
associated with cognitive performance in older individuals. Mean (6SD) eGFR, estimated by the CKD-EPI
(Chronic Kidney Disease Epidemiology Collaboration) creatinine–cystatin C equation (eGFRcr-cys), was
88.46 14.6 mL/min/1.73 m2. eGFRcr-cys was not associated with any of the domains of cognitive
performance after full adjustment. However, significant interaction terms (P for interaction , 0.05)
suggested that eGFRcr-cys was associated with cognitive performance in older individuals.
Limitations: Cross-sectional design, which limited causal inferences.
Conclusions: In the entire study population, albuminuria was independently associated with lower infor-
mation processing speed, whereas eGFRcr-cys was not associated with cognitive performance. However, both
were more strongly and extensively associated with cognitive performance in older individuals.
Am J Kidney Dis. 69(2):179-191. ª 2016 by the National Kidney Foundation, Inc.
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n older individuals, both reduced estimated glomer-I ular filtration rate (eGFR) and albuminuria have
been associated with lower cognitive performance,1-17
although not consistently so.4,14,16,18,19
Conceptually, reduced GFR may lead to the accu-
mulation of neurotoxins or may represent lifetime
exposure to cardiovascular disease (CVD) risk factors or
CVD itself,20 whereas albuminuria may be a biomarker
of generalized endothelial dysfunction.21,22 Thereby,
reduced GFRmay play a direct role in the pathobiology
of cognitive decline,20 but may also, similar to albu-
minuria, act as a biomarker of any underlying mecha-
nisms involved in cognitive decline.20,22
However, few studies19,23-26 have examinedwhether
the associations of eGFR19,23-25 and albuminuria19,26
with cognitive performance are confined to older
individuals or may be extended to the middle-aged (ie,
40- to 65-year-old) population. This is important
because it can be hypothesized that in middle-aged
individuals, brain reserve capacity (ie, “the amount of
damage that can be sustained before reaching a
threshold for clinical expression”27p449) is higher, as a
result of which changes in cognitive performance are
subtle.27,28 In addition, some studies may have been
affected by residual confounding due to incomplete
adjustment for CVD risk factors.
We thereforefirst examined the associations of eGFR
and albuminuria with several domains of cognitive
performance (ie, memory function, information pro-
cessing speed, and executive function) in 40- to
75-year-old individuals who participated in the
population-based Maastricht Study. Second, we
exploredwhether any such associations differed by age.
METHODS
The Maastricht Study Population and Design
In this study, we used data from The Maastricht Study, an obser-
vational prospective population-based cohort study. The rationale
and methodology have been described previously.29 In brief, the
study focuses on the etiology, pathophysiology, complications, and
comorbid conditions of type 2 diabetes (T2DM) and is characterized
by an extensive phenotyping approach. Eligible for participation
were all individuals aged 40 to 75years and living in the southern part
of the Netherlands. Participants were recruited through mass media
campaigns and from the municipal registries and the regional Dia-
betes Patient Registry by mailings. Recruitment was stratified ac-
cording to known T2DM status, with an oversampling of individuals
with T2DM, for reasons of efficiency. The present report includes
cross-sectional data from the first 3,451 participants, who completed
the baseline survey between November 2010 and September 2013.
The examinations of each participant were performed within a time
window of 3 months. The study has been approved by the institu-
tional medical ethics committee (NL31329.068.10) and theMinister
of Health, Welfare and Sports of the Netherlands (permit 131088-
105234-PG) and was conducted in accordance with the Declaration
of Helsinki. All participants gave written informed consent.180Kidney Function
GFR was estimated by the CKD-EPI (Chronic Kidney Disease
Epidemiology Collaboration) serum creatinine and serum cystatin C
equation (eGFRcr-cys)
30 for the primary analyses. For additional an-
alyses, GFR was estimated by the CKD-EPI serum creatinine equa-
tion (eGFRcr),
30 the CKD-EPI serum cystatin C equation
(eGFRcys),
30 and the isotope-dilution mass spectrometry (IDMS)-
traceable 4-variable MDRD (Modification of Diet in Renal Disease)
Study equation.31 Serum creatinine was measured with a Jaffé
method traceable to IDMS (due to a change of supplier, 2 instruments
were used in the study, the Beckman Synchron LX20, Beckman
Coulter Inc, and the Roche Cobas 6000, F. Hoffmann-La Roche Ltd).
Serum cystatin C was measured with a particle-enhanced immuno-
turbidimetric assay standardized against ERM-DA471/IFCC (Inter-
national Federation of Clinical Chemistry and Laboratory Medicine)
reference material (Roche Cobas 8000, F. Hoffman-La Roche Ltd).
To assess urinary albumin excretion (UAE), participants were
requested to collect two 24-hour urine samples. Urinary albumin
concentration was measured with a standard immunoturbidimetric
assay by an automatic analyzer (due to a change of supplier, by the
Beckman SynchronLX20 and theRocheCobas 6000) andmultiplied
by collection volume to obtain 24-hour UAE. A urinary albumin
concentration below the detection limit of the assay (2 mg/L for the
Beckman Synchron LX20 and 3 mg/L for the Roche Cobas 6000)
was set at 1.5 mg/L before multiplying by collection volume. Only
urine collectionswith a collection time between 20 and 28 hourswere
considered valid. If needed, UAE was extrapolated to 24-hour
excretion. For this study, UAE was preferably based on the average
of 2 (available in 91.3% of participants) 24-hour urine collections.
Cognitive Performance
Cognitive performance was assessed by a concise (30-minute)
neuropsychological test battery.29 For conceptual clarity, test scores
were standardized and divided into 3 cognitive domains (ie,
memory function, information processing speed, and executive
function). A detailed description of neuropsychological tests and
methods used to calculate domain scores is provided in Item S1
(provided as online supplementary material). Briefly, memory
function was evaluated using the Verbal Learning Test32 by
calculating the standardized average of total immediate and delayed
recall scores. The composite score for information processing speed
was derived from the Stroop Color-Word Test Part I and II,33 the
Concept Shifting Test Part A and B,34 and the Letter-Digit Sub-
stitution Test.35 Executive function was assessed by the Stroop
Color-Word Test Part III and the Concept Shifting Test Part C. If
necessary, individual test scores were log-transformed to fulfill the
normality assumption and/or inverted so that higher scores indi-
cated better cognitive performance. In addition, an overall cognitive
performance score was calculated as the standardized average of
the 3 domain scores and used as a summary score.
Potential Confounders
We assessed fasting glucose, hemoglobin A1c, cholesterol (total,
high-density lipoprotein, and low-density lipoprotein), tri-
glycerides, glucose metabolism status, body mass index, waist
circumference, hip circumference, office blood pressure, 24-hour
average ambulatory blood pressure, medication use, smoking
behavior, alcohol consumption, educational level, (subjective)
physical activity, current major depressive episode, and prevalent
CVD as described previously.29,36 Further details and definitions
of potential confounders are provided in Item S1.
Statistical Analyses
All analyses were performed with IBM SPSS Statistics, version
22.0 (IBM Corp). Population characteristics were presented strat-
ified by eGFRcr-cys and albuminuria categories.Am J Kidney Dis. 2017;69(2):179-191
Kidney Function and Cognitive PerformanceAssociations of eGFRcr-cys and albuminuria with the composite
scores of cognitive performance were evaluated with multivariable
linear regression analyses. eGFRcr-cys was analyzed as a categor-
ical ($90, 60-,90, and ,60 mL/min/1.73 m2) and a continuous
(per 10–mL/min/1.73 m2 lower eGFRcr-cys) variable. Similarly,
UAE was analyzed as a categorical (,15, 15-,30, and $30 mg/
24 h) and, after log base 2 transformation, a continuous (per
doubling of UAE) variable. The regression coefficients (bs)
represent the standard deviation (SD) difference in the cognitive
domain scores as compared to eGFRcr-cys $ 90 mL/min/1.73 m
2,
per 10–mL/min/1.73 m2 lower eGFRcr-cys, as compared to
UAE , 15 mg/24 h, and per doubling of UAE, respectively. For
example, b of 0.01 is 1% of 1 SD.
We adjusted for potential confounders as follows (more details
on variable handling are provided in Item S1): model 1, unadjusted
model; model 2, age, sex, educational level, and glucose meta-
bolism status; model 3, model 2 plus waist circumference, total to
high-density lipoprotein cholesterol ratio, triglyceride level, use of
lipid-modifying medication, smoking behavior, and alcohol con-
sumption; model 4, model 3 plus UAE (categorical) or eGFRcr-cys
(continuous); model 5a, model 4 plus office systolic blood pres-
sure, use of antihypertensive medication, prevalent CVD, and
depression; and model 5b, as model 5a but with replacement of
office systolic blood pressure by 24-hour average ambulatory
systolic blood pressure. Blood pressure, prevalent CVD, and
depression may be confounders, but may also mediate an associ-
ation between kidney function and cognitive performance (eg,
hypertension and stroke, which are risk factors for cognitive
decline,20 may result from kidney disease37-39) or be descending
proxies of such intermediates (eg, depression and cognitive per-
formance may have cerebral small-vessel disease as a common
cause40). Therefore, these variables were added in a separate
model because a model including these variables is at risk of
overadjustment bias.41
We used interaction terms added to model 1 to examine whether
the associations of eGFRcr-cys and albuminuria with cognitive
performance were modified by age (P for interaction , 0.1 was
considered statistically significant).
Adjusted mean values of the composite score of information
processing speed per albuminuria category were estimated with
general linear models with adjustment for age, sex, educational
level, and glucose metabolism status (model 2).
Several additional analyses were performed to assess the
robustness of results. First, eGFRcr-cys was replaced with eGFR
based on the MDRD Study equation, eGFRcr, or eGFRcys, because
recent studies indicated that cystatin C–based estimates are more
strongly associated with cognitive performance.10,11 Second, we
adjusted for a quadratic association between age and cognitive
performance.32-34 Third, we restricted analyses to participants with
UAE # 300 mg/24 h and participants with two 24-hour urine
collections and excluded participants with a Mini-Mental State
Examination score, 24, suggesting frank cognitive impairment.42
Fourth, analyses were repeated with replacement of the following:
office systolic blood pressure by office diastolic blood pressure,
office mean arterial pressure, office pulse pressure, their 24-hour
average ambulatory equivalents, and the presence of hyperten-
sion; use of antihypertensive medication by the use of specifically
renin-angiotensin system inhibitors; and waist circumference by
waist-to-hip ratio or body mass index. Fifth, we additionally
adjusted for total or moderate to vigorous physical activity. Sixth,
we used interaction terms added to model 1 to examine whether
associations were modified by glucose metabolism status given the
design of The Maastricht Study. Seventh, we performed multiple
imputation with fully conditional specification (maximal 10 iter-
ations, 20 data sets) under the missing at random assumption.43,44
Continuous eGFRcr-cys and UAE, as well as the dependent and
potential confounding variables of models 5a and 5b, wereAm J Kidney Dis. 2017;69(2):179-191included in the imputation model. Overall cognitive performance
was calculated as the standardized average of the 3 imputed
cognitive domain scores.
Variance inflation factors were ,2.5 for all nonmultiplicative
variables.
RESULTS
Characteristics of the Study Population
Figure 1 is a flow diagram delineating the derivation
of the final study population. In total, 2,987 partici-
pants had complete data for all variables in model 5a
and were included in the analyses. None of the par-
ticipants was on dialysis treatment. Participants with
missing data (n 5 420) more often had T2DM, hy-
pertension, prevalent CVD, and a lower educational
level. In addition, they had lower eGFRs estimated by
cystatin C–based equations, higher UAEs, and lower
scores on all domains of cognitive performance.
Table 1 shows the study population characteristics
overall stratified by albuminuria categories. Table S1
shows study population characteristics stratified by
eGFRcr-cys categories. By design, 791 (26.5%) par-
ticipants had T2DM. The study population, which had
a mean (6SD) age of 59.66 8.2 years, was well
educated (41.2% higher vocational education or uni-
versity level of education). In general, participants
with higher albuminuria and participants with lower
eGFRcr-cys were older, were more often men, were
less educated, more often had T2DM and CVD, and
had a worse CVD risk profile.
Albuminuria and Cognitive Performance
UAE was ,15 mg/24 h in 2,439 (81.7%) partici-
pants, 15 to ,30 mg/24 h in 309 (10.3%),
and $30 mg/24 h in 239 (8.0%). Participants with
higher UAE had lower performance on each of the
cognitive domains (Table 1).
After adjustment for age, sex, glucose metabolism
status, and educational level (Table 2, model 2) and
with UAE , 15 mg/24 h as the reference category,
UAE $ 30 mg/24 h was associated with lower overall
cognitive performance (b [SD difference] 5 20.149;
95% confidence interval [CI], 20.256 to 20.043),
lower information processing speed (b 5 20.172;
95% CI, 20.286 to 20.058; Fig 2), and borderline
statistically significantly lower memory function
(b 5 20.110; 95% CI, 20.229 to 0.008). These as-
sociations were attenuated after further adjustment for
the variables of models 3 to 5, but remained statistically
significant for overall cognitive performance
(b 5 20.110; 95% CI, 20.217 to 20.002; model 5a)
and information processing speed (b 5 20.148; 95%
CI, 2 0.263 to 20.033; model 5a).
Continuous albuminuria was not statistically
significantly associated with cognitive performance
after full adjustment (Table 3, model 5a).181
Figure 1. Flow diagram delineates
the derivation of the final study popula-
tion. *Categories of missing items were
not mutually exclusive. Abbreviations:
eGFRcr-cys, estimated glomerular filtra-
tion rate based on creatinine and cystatin
C levels; CVD, cardiovascular disease.
Martens et alResults were similar when we adjusted for 24-hour
average ambulatory systolic blood pressure instead of
office systolic blood pressure (Tables 2 and 3, model 5b).
Albuminuria and Cognitive Performance: Test for
Interaction With Age
Analyses with interaction terms showed that the as-
sociation between continuous albuminuria and cogni-
tive performance was stronger at older age, to such an
extent that the interaction terms indicated a 20.038
(executive function) to20.030 (information processing
speed) difference in the b of albuminuria per 10 years
older age (model 1; P for interaction , 0.05 for all
cognitive domains except memory function). The latter
implied that albuminuria was not associated with
cognitive performance in 50-year-old individuals,
whereas in 70-year-old individuals, it was associated
with lower overall cognitive performance, information182processing speed, and executive function (Table S2).
Analyses stratified according to age tertiles showed a
similar pattern (Table S3).
eGFR and Cognitive Performance
Mean (6SD) eGFRcr-cys was 88.46 14.6 mL/min/
1.73 m2 (Table 1). There were 1,463 (49.0%) partici-
pantswho had eGFRcr-cys $ 90 mL/min/1.73 m
2; 1,413
(47.3%) had eGFRcr-cys 60 to ,90 mL/min/1.73 m
2;
and 111 (3.7%) had eGFRcr-cys ,60 mL/min/1.73 m
2.
Participants with lower eGFRcr-cys had lower scores on
each of the cognitive domains (Table S1).
After adjustment for age, sex, glucose metabolism
status, and educational level (Table 4, model 2),
eGFRcr-cys , 60 mL/min/1.73 m
2 was associated with
lower overall cognitive performance (b 5 20.191;
95% CI, 20.346 to 20.035), lower information
processing speed (b 5 20.215; 95% CI, 20.381Am J Kidney Dis. 2017;69(2):179-191
Kidney Function and Cognitive Performanceto 20.049), and borderline statistically significantly
lowermemory function (b520.151; 95%CI,20.323
to 0.022). After further adjustment for the variables of
models 3 to 5, these associations were attenuated and
no longer statistically significant.
Similarly, continuous eGFRcr-cys was not statisti-
cally significantly associated with cognitive perfor-
mance after full adjustment (Table 5, model 5a).
Results were similar when we adjusted for 24-hour
average ambulatory systolic blood pressure instead of
office systolic blood pressure (Tables 4 and 5, model 5b).
eGFR and Cognitive Performance: Test for Interaction
With Age
Analyses with interaction terms showed that the as-
sociation between continuous eGFRcr-cys and cognitive
performance was stronger at older age, to such an extent
that the interaction terms indicated a 20.043 (overall
cognitive performance) to 20.031 (memory function)
difference in the b of eGFRcr-cys per 10 years older age
(model 1, P for interaction , 0.05 for all cognitive
domains). The latter implied that eGFRcr-cys was not
associated with cognitive performance in 50-year-old
individuals, whereas in 70-year-old individuals, it was
associated with lower overall cognitive performance
and borderline statistically significantly lower memory
function and executive function (Table S4). Additional
age-stratified analyses showed a similar pattern, but
were hampered by a loss of statistical power (Table S5).
Additional Analyses
When eGFRcr-cys was replaced with eGFR based on
theMDRDStudy equation, eGFRcr, or eGFRcys, results
did not materially change, except for the association of
eGFRcr-cys with memory function, that is, point esti-
mates as compared to eGFRcr-cys were smaller with
creatinine-based equations and larger with the cystatin
C-based equation (Table S6).
Additionally, results were not materially altered in
the following scenarios (Tables S7 and S8): when we
adjusted for a quadratic association between age and all
scores of cognitive performance; when we replaced
office systolic blood pressure with either office diastolic
blood pressure, office mean arterial pressure, office
pulse pressure, presence of hypertension, 24-hour
average ambulatory (n5 2,644) diastolic blood pres-
sure, mean arterial pressure, or pulse pressure; when we
replaced the use of antihypertensive medication with
the use of a renin-angiotensin system inhibitor or
replaced waist circumference with waist-to-hip ratio or
body mass index; when results were additionally
adjusted for either total (n5 2,635) or moderate to
vigorous physical activity (n5 2,634); when we
restricted analyses to participants with UAE# 300 mg/
24 h (n5 2,969) and participants with 2 urine collec-
tions (n5 2,727); and when we excluded participantsAm J Kidney Dis. 2017;69(2):179-191with a Mini-Mental State Examination score , 24
(n5 10). In addition, no interactions between either
albuminuria or eGFRcr-cys and glucose metabolism
status were found (P for interaction . 0.1), except for
the association of UAE of 15 to ,30 mg/24 h with
overall cognitive performance (P for interaction5 0.1)
and executive function (P for interaction 5 0.08), and
the association of eGFRcr-cys , 60 mL/min/1.73 m
2
with information processing speed (P for interaction5
0.04) in participants with impaired glucose metabolism
only. Finally, results of multiple imputation analyses
were similar to complete case analyses, with the
exception that lower eGFRcr-cys was borderline statis-
tically significantly associated with lower memory
function after multiple imputation (Table S9).
DISCUSSION
This study of the associations of eGFR and
albuminuria with cognitive performance in 40- to 75-
year-old individuals had 3 main findings. First,
albuminuria with UAE $ 30 mg/24 h was associated
with lower information processing speed, independent
of educational level, CVD risk factors (including
eGFRcr-cys), and lifestyle factors. Second, eGFRcr-cys
was not associated with any of the domains of
cognitive performance after adjustment for educa-
tional level, CVD risk factors (including albumin-
uria), and lifestyle factors. Third, associations of
albuminuria and eGFRcr-cys seemed to be modified by
age, to such an extent that both were more strongly
and extensively associated with cognitive perfor-
mance in older individuals.
Albuminuria with UAE $ 30 mg/24 h was asso-
ciated with information processing speed, whereas no
associations were observed with memory function
and executive function. As compared to continuous
UAE, the categorical approach may have been less
affected by the day-to-day variability in UAE and
therefore nondifferential misclassification with bias
toward the null. In addition, the continuous (expo-
nential) model, although reasonable, may not have
perfectly fitted the association. However, we can not
exclude residual confounding with the categorical
approach or the play of chance.
The absence of an association with executive
function is in agreement with 2 studies in a similar
age group,19,26 but contrasts with studies in older
individuals,12-14,17 which have shown an association
between albuminuria and executive function. One
explanation for this discrepancy is that cognitive
decline is more subtle in middle-aged individuals due
to higher brain reserve capacity in this age group. The
statistically significant interaction between age and
albuminuria, which suggested a stronger association
between albuminuria and cognitive performance,
including executive function, with increasing age,183
Table 1. Clinical Characteristics of Study Population Overall and Stratified According to Albuminuria Categories
Study Population
(N 5 2,987)
Albuminuria Category
,15 mg/24 h
(n 5 2,439)
15-,30 mg/24 h
(n 5 309)
$30 mg/24 h
(n 5 239)
Demographics
Age, y 59.6 6 8.2 59.0 6 8.2 61.8 6 8.2 62.4 6 7.7
Male sex 1,527 (51.1) 1,166 (47.8) 186 (60.2) 175 (73.2)
Educational level
Low 468 (15.7) 348 (14.3) 55 (17.8) 65 (27.2)
Intermediate 1,290 (43.2) 1,065 (43.7) 134 (43.4) 91 (38.1)
High 1,229 (41.2) 1,026 (42.1) 120 (38.8) 84 (34.7)
Prevalent CVD 481 (16.1) 352 (14.4) 61 (19.7) 69 (28.5)
Lifestyle variables
Smoking behavior
Never smoker 1,048 (35.1) 903 (37.0) 89 (28.8) 56 (23.4)
Former smoker 1,549 (51.9) 1,236 (50.7) 177 (57.3) 136 (56.9)
Current smoker 390 (13.1) 300 (12.3) 43 (13.9) 47 (19.7)
Alcohol consumption
None 537 (18.0) 419 (17.2) 58 (18.8) 60 (25.1)
Lowa 1,658 (55.5) 1,368 (56.1) 170 (55.0) 120 (50.2)
Highb 792 (26.5) 652 (26.7) 81 (26.2) 59 (24.7)
Total physical activity, h/wkc 13.0 [8.3-18.8] 13.4 [8.5-18.8] 12.9 [7.5-18.6] 11.3 [6.3-18.5]
Moderate to vigorous physical activity, h/wkc 4.5 [2.3-8.0] 4.6 [2.8-8.0] 4.0 [1.5-8.2] 3.3 [1.5-7.3]
Metabolic variables
BMI categoryd
Normal weight: ,25 kg/m2 1,045 (35.0) 925 (37.9) 73 (23.6) 47 (19.7)
Overweight: 25-,30 kg/m2 1,286 (43.1) 1,043 (42.8) 144 (46.6) 99 (41.4)
Obesity: $30 kg/m2 655 (21.9) 470 (19.3) 92 (29.8) 93 (38.9)
Waist circumference, cm
Men 101.36 11.8 99.7 6 11.1 105.36 11.6 107.76 13.7
Women 89.9 6 12.8 89.3 6 12.2 93.6 6 16.1 96.16 16.1
Waist-to-hip ratioe
Men 1.00 6 0.07 0.99 6 0.07 1.02 6 0.07 1.036 0.08
Women 0.88 6 0.07 0.87 6 0.07 0.89 6 0.08 0.926 0.09
Blood pressure
Office systolic, mm Hg 134.86 18.1 133.16 17.4 141.16 18.2 143.76 20.4
Office diastolic, mm Hg 76.3 6 9.9 75.9 6 9.8 77.8 6 10.6 78.1 6 9.7
24-h average ambulatory systolic, mm Hgf 119.06 11.7 117.76 11.0 123.16 12.4 126.46 13.9
24-h average ambulatory diastolic, mm Hgf 73.6 6 7.2 73.2 6 7.0 75.0 6 8.3 75.4 6 7.5
Hypertension 1,659 (55.5) 1,240 (50.8) 222 (71.8) 197 (82.4)
Glucose metabolism status
Normal glucose metabolism 1,732 (58.0) 1,532 (62.8) 130 (42.1) 70 (29.3)
Impaired fasting glucose 128 (4.3) 103 (4.2) 17 (5.5) 8 (3.3)
Impaired glucose tolerance 336 (11.2) 290 (11.9) 25 (8.1) 21 (8.8)
T2DM 791 (26.5) 514 (21.1) 137 (44.3) 140 (58.6)
Fasting glucose, mg/dLg
Without T2DM 96.0 6 9.9 95.7 6 9.7 97.7 6 10.4 99.56 10.3
With T2DM 142.86 36.9 138.66 31.6 143.86 39.5 157.36 47.4
HbA1c, %
h
Without T2DM 5.56 0.4 5.56 0.4 5.56 0.4 5.66 0.4
With T2DM 6.96 1.0 6.86 0.8 7.06 1.1 7.46 1.4
Cholesterol
Total, mg/dL 203.46 44.6 206.36 43.9 193.26 46.1 186.76 45.2
HDL, mg/dL
Men 51.3 6 14.5 52.1 6 14.2 48.0 6 13.6 49.66 16.5
Women 67.0 6 18.6 67.5 6 18.5 64.3 6 17.6 63.46 20.5
LDL, mg/dL 120.26 39.9 122.86 39.3 112.46 40.2 103.86 39.8
Triglycerides, mg/dL 106.3 [77.9-152.3] 103.6 [76.2-146.1] 116.0 [86.4-169.2] 129.3 [96.5-193.1]
Total to HDL cholesterol ratio 3.76 1.2 3.76 1.2 3.86 1.2 3.86 1.2
(Continued)
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Table 1 (Cont’d). Clinical Characteristics of Study Population Overall and Stratified According to Albuminuria Categories
Study Population
(N 5 2,987)
Albuminuria Category
,15 mg/24 h
(n 5 2,439)
15-,30 mg/24 h
(n 5 309)
$30 mg/24 h
(n 5 239)
Kidney function
eGFRcr-cys, mL/min/1.73 m
2 88.4 6 14.6 89.2 6 13.9 86.9 6 16.1 82.16 17.8
eGFRcr, mL/min/1.73 m
2 84.7 6 13.8 85.1 6 13.3 84.1 6 14.8 81.16 16.2
eGFRcys, mL/min/1.73 m
2 90.2 6 16.2 91.3 6 15.4 87.6 6 17.7 81.76 19.5
eGFRMDRD, mL/min/1.73 m
2 80.6 6 15.4 80.7 6 14.9 81.5 6 16.6 79.26 19.0
UAE rate, mg/24 h 6.6 [4.0-11.7] 5.6 [3.7-8.3] 19.4 [16.6-23.9] 68.3 [41.6-114.1]
UAE category
,15 mg/24 h 2,439 (81.7) — — —
15-,30 mg/24 h 309 (10.3) — — —
$30 mg/24 h 239 (8.0) — — —
Medication
Antihypertensive medication 1,157 (38.7) 840 (34.4) 153 (49.5) 164 (68.6)
Renin-angiotensin system inhibitor 867 (29.0) 605 (24.8) 121 (39.2) 141 (59.0)
Lipid-modifying medication 1,033 (34.6) 747 (30.6) 141 (45.6) 145 (60.7)
Mental health and cognitive performance
Current major depressive episode 109 (3.6) 69 (2.8) 23 (7.4) 17 (7.1)
Overall cognitive performance 0.00 6 1.00 0.08 6 0.98 20.23 6 1.05 20.51 6 1.00
Memory function 0.00 6 1.00 0.06 6 0.98 20.19 6 1.03 20.42 6 0.99
Information processing speed 0.00 6 1.00 0.07 6 0.97 20.16 6 1.01 20.48 6 1.08
Executive function 0.00 6 1.00 0.06 6 0.98 20.19 6 1.08 20.32 6 1.00
Note: Values for categorical variables are given as number (percentage); values for continuous variables, as mean 6 standard
deviation or median [interquartile range]. Conversion factors for units: fasting glucose in mg/dL to mmol/L, 30.05551; HbA1c in % to
mmol/mol, 10.93 3 HbA1c [%]1 23.5; cholesterol in mg/dL to mmol/L, 30.02586; triglycerides in mg/dL to mmol/L, 30.01129.
Abbreviations: BMI, body mass index; CVD, cardiovascular disease; eGFRcr, creatinine-based estimated glomerular filtration rate;
eGFRcr-cys, estimated glomerular filtration rate based on creatinine and cystatin C levels; eGFRcys, cystatin C–based estimated
glomerular filtration rate; eGFRMDRD, estimated glomerular filtration rate based on 4-variable Modification of Diet in Renal Disease
Study equation; HbA1c, hemoglobin A1c (glycated hemoglobin); HDL, high-density lipoprotein; LDL, low-density lipoprotein; T2DM, type
2 diabetes mellitus; UAE, urinary albumin excretion.
aLow alcohol consumption: women, 7 or fewer glasses per week; men, 14 or fewer glasses per week.
bHigh alcohol consumption: women, more than 7 glasses per week; men, more than 14 glasses per week.
cAvailable for 2,635 (total physical activity) and 2,634 (moderate to vigorous physical activity) participants.
dAvailable for 2,986 participants.
eAvailable for 2,986 participants.
fAvailable for 2,644 participants.
gAvailable for 2,985 participants.
hAvailable for 2,980 participants.
Kidney Function and Cognitive Performancesupports this view. In addition, the study population
largely consisted of highly educated individuals who
may be better able to maximize cognitive perfor-
mance in the face of brain damage,27,28 and infor-
mation processing speed has been shown to be the
domain most affected in individuals with vascular
cognitive decline.45
Generalized endothelial dysfunctionmay provide an
explanation for the link between albuminuria and
cognitive performance.21,22 According to this concept,
endothelial dysfunction of the microcirculation on the
one hand causes albuminuria, and on the other hand,
cerebral small-vessel disease. It has been hypothesized
that cerebral small-vessel disease increases blood-
brain barrier permeability, which leads to extravasa-
tion of blood substances and subsequent neuronal
damage.22,46 Indeed, albuminuria has been associatedAm J Kidney Dis. 2017;69(2):179-191with magnetic resonance imaging findings of cerebral
small-vessel disease47 and the latter predicts cognitive
decline.48
Reduced GFR may lead to neuronal damage due to
the accumulation of neurotoxins and/or may reflect
disease processes underlying cognitive decline, for
example, exposure to CVD risk factors and CVD it-
self.20 The attenuation of the regression coefficients
after adjustment for CVD risk factors supports the
latter. However, the results of this study contrast with
those of previous studies in middle-aged23,25 and
older individuals,1,5,6,8,9 which have shown indepen-
dent associations between lower creatinine-based es-
timates of GFR and the studied domains of cognitive
performance. This is potentially explained by the
younger mean age of participants in the present study
population. The statistically significant interaction185
Table 2. Multivariable Linear Regression Analyses of Association Between Categorical Albuminuria and Cognitive Performance
Modela UAE
Overall Cognitive Performance Memory Function Information Processing Speed Executive Function
b (95% CI) P b (95% CI) P b (95% CI) P b (95% CI) P
1 ,15 mg/24 h Reference Reference Reference Reference
15-,30 mg/24 h 20.305 (20.422 to 20.189) ,0.001 20.252 (20.369 to 20.134) ,0.001 20.226 (20.343 to 20.109) ,0.001 20.246 (20.364 to 20.129) ,0.001
$30 mg/24 h 20.593 (20.724 to 20.462) ,0.001 20.481 (20.613 to 20.350) ,0.001 20.548 (20.679 to 20.417) ,0.001 20.381 (20.513 to 20.249) ,0.001
2 ,15 mg/24 h Reference Reference Reference Reference
15-,30 mg/24 h 20.041 (20.134 to 0.052) 0.4 20.040 (20.143 to 0.063) 0.4 0.002 (20.097 to 0.102) 0.9 20.057 (20.162 to 0.048) 0.3
$30 mg/24 h 20.149 (20.256 to 20.043) 0.006 20.110 (20.229 to 0.008) 0.07 20.172 (20.286 to 20.058) 0.003 20.075 (20.195 to 0.044) 0.2
3 ,15 mg/24 h Reference Reference Reference Reference
15-,30 mg/24 h 20.036 (20.128 to 0.057) 0.5 20.035 (20.138 to 0.069) 0.5 0.006 (20.093 to 0.105) 0.9 20.053 (20.158 to 0.052) 0.3
$30 mg/24 h 20.128 (20.235 to 20.021) 0.02 20.083 (20.202 to 0.036) 0.2 20.159 (20.273 to 20.044) 0.007 20.067 (20.188 to 0.054) 0.3
4 ,15 mg/24 h Reference Reference Reference Reference
15-,30 mg/24 h 20.036 (20.129 to 0.057) 0.4 20.035 (20.138 to 0.068) 0.5 0.006 (20.093 to 0.105) 0.9 20.053 (20.158 to 0.051) 0.3
$30 mg/24 h 20.124 (20.232 to 20.017) 0.02 20.078 (20.198 to 0.041) 0.2 20.158 (20.273 to 20.044) 0.007 20.065 (20.186 to 0.056) 0.3
5a ,15 mg/24 h Reference Reference Reference Reference
15-,30 mg/24 h 20.024 (20.117 to 0.069) 0.6 20.028 (20.131 to 0.076) 0.6 0.011 (20.089 to 0.110) 0.8 20.038 (20.143 to 0.067) 0.5
$30 mg/24 h 20.110 (20.217 to 20.002) 0.05 20.068 (20.188 to 0.052) 0.3 20.148 (20.263 to 20.033) 0.01 20.050 (20.171 to 0.071) 0.4
5b ,15 mg/24 h Reference Reference Reference Reference
15-,30 mg/24 h 20.038 (20.137 to 0.062) 0.5 20.035 (20.146 to 0.076) 0.5 0.006 (20.100 to 0.112) 0.9 20.057 (20.169 to 0.055) 0.3
$30 mg/24 h 20.133 (20.248 to 20.018) 0.02 20.108 (20.237 to 0.021) 0.1 20.177 (20.300 to 20.054) 0.005 20.034 (20.164 to 0.096) 0.6
Note: Regression coefficients (bs) represent the standard deviation difference in the cognitive domain scores as compared with participants with UAE , 15 mg/24 h.
Abbreviations: CI, confidence interval; eGFRcr-cys, estimated glomerular filtration rate based on creatinine and cystatin C levels; UAE, urinary albumin excretion.
aModel 1: unadjusted model; model 2: model 1 1 age, sex, educational level, and glucose metabolism status; model 3: model 2 1 waist circumference, total to high-density lipoprotein
cholesterol ratio, triglyceride level, use of lipid-modifying medication, smoking behavior, and alcohol consumption; model 4: model 3 1 eGFRcr-cys (continuous); model 5a: model 4 1 office
systolic blood pressure, use of antihypertensive medication, prevalent cardiovascular disease, and depression; model 5b: similar to model 5a but adjusted for ambulatory systolic blood pressure
instead of office systolic blood pressure (missing in 343 participants).
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Figure 2. Association between albuminuria and information
processing speed. Adjusted mean values of the composite score
of information processing speed are expressed per albuminuria
category. Mean values were adjusted for age, sex, educational
level, and glucose metabolism status (model 2). Bars indicate
95% confidence intervals. P values were derived from the
same models. *P , 0.01 as compared with participants with uri-
nary albumin excretion , 15 mg/24 h. Abbreviation: SD, stan-
dard deviation.
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Kidney Function and Cognitive Performancebetween age and eGFRcr-cys, which suggested a
stronger association between eGFRcr-cys and cognitive
performance with increasing age, supports this view.
Additionally, the study population largely consisted
of highly educated individuals and few participants
had an eGFRcr-cys , 60 mL/min/1.73 m
2.
We used an equation based on both serum creati-
nine and serum cystatin C levels to estimate GFR in
our primary analyses.30 However, additional analyses
showed a stronger association between eGFR and
cognitive performance (ie, memory function) when an
equation based on cystatin C level only was used.
This is in agreement with 2 previous studies in older
individuals.10,11 A clear explanation for these results
cannot be derived from this study. Cystatin C may be
a more sensitive biomarker of GFR than creatinine in
populations with more comorbid conditions,49 which
allows for the detection of even a subtle association
between eGFR and memory function. Alternatively,
cystatin C level may be associated with other de-
terminants of cognitive decline, such as visceral
adiposity and inflammation.49
Major strengths of the present study were its exten-
sive assessment of cognitive performance and detailed
characterization of the study population, which allowed
adjustment for an extensive series of potential con-
founders, including 24-hour average ambulatory blood
pressure. However, this study also had some limita-
tions. First, the cross-sectional design limited causal
inferences. Second, we cannot exclude residual con-
founding despite adjustment for an extensive series
of potential confounders. For example, inflammationAm J Kidney Dis. 2017;69(2):179-191 187
Table 4. Multivariable Linear Regression Analyses of the Association Between Categorical eGFRcr-cys and Cognitive Performance
Modela eGFRcr-cys
Overall Cognitive Performance Memory Function Information Processing Speed Executive Function
b (95% CI) P b (95% CI) P b (95% CI) P b (95% CI) P
1 $90 mL/min/1.73 m2 Reference Reference Reference Reference
60-,90 mL/min/1.73 m2 20.363 (20.435 to 20.292) ,0.001 20.239 (20.312 to 20.167) ,0.001 20.334 (20.406 to 20.263) ,0.001 20.300 (20.372 to 20.228) ,0.001
,60 mL/min/1.73 m2 20.943 (21.131 to 20.755) ,0.001 20.649 (20.839 to 20.458) ,0.001 20.912 (21.101 to 20.724) ,0.001 20.703 (20.893 to 20.513) ,0.001
2 $90 mL/min/1.73 m2 Reference Reference Reference Reference
60-,90 mL/min/1.73 m2 20.044 (20.105 to 0.016) 0.2 20.037 (20.105 to 0.030) 0.3 20.030 (20.096 to 0.035) 0.4 20.037 (20.106 to 0.031) 0.3
,60 mL/min/1.73 m2 20.191 (20.346 to 20.035) 0.02 20.151 (20.323 to 0.022) 0.09 20.215 (20.381 to 20.049) 0.01 20.089 (20.264 to 0.085) 0.3
3 $90 mL/min/1.73 m2 Reference Reference Reference Reference
60-,90 mL/min/1.73 m2 20.022 (20.083 to 0.039) 0.5 20.024 (20.092 to 0.045) 0.5 20.012 (20.078 to 0.053) 0.7 20.016 (20.085 to 0.053) 0.7
,60 mL/min/1.73 m2 20.138 (20.294 to 0.017) 0.08 20.107 (20.280 to 0.066) 0.2 20.177 (20.344 to 20.011) 0.04 20.048 (20.224 to 0.128) 0.6
4 $90 mL/min/1.73 m2 Reference Reference Reference Reference
60-,90 mL/min/1.73 m2 20.020 (20.082 to 0.041) 0.5 20.023 (20.091 to 0.046) 0.5 20.009 (20.075 to 0.056) 0.8 20.015 (20.084 to 0.054) 0.7
,60 mL/min/1.73 m2 20.118 (20.275 to 0.039) 0.1 20.094 (20.269 to 0.080) 0.3 20.152 (20.319 to 0.016) 0.08 20.037 (20.214 to 0.140) 0.7
5a $90 mL/min/1.73 m2 Reference Reference Reference Reference
60-,90 mL/min/1.73 m2 20.017 (20.078 to 0.044) 0.6 20.022 (20.090 to 0.046) 0.5 20.003 (20.068 to 0.063) 0.9 20.014 (20.083 to 0.055) 0.7
,60 mL/min/1.73 m2 20.102 (20.259 to 0.056) 0.2 20.087 (20.263 to 0.089) 0.3 20.124 (20.292 to 0.045) 0.2 20.031 (20.209 to 0.147) 0.7
5b $90 mL/min/1.73 m2 Reference Reference Reference Reference
60-,90 mL/min/1.73 m2 20.024 (20.088 to 0.041) 0.5 20.026 (20.098 to 0.047) 0.5 20.010 (20.079 to 0.059) 0.8 20.020 (20.092 to 0.053) 0.6
,60 mL/min/1.73 m2 20.112 (20.279 to 0.055) 0.2 20.094 (20.281 to 0.093) 0.3 20.172 (20.350 to 0.006) 0.06 20.002 (20.190 to 0.186) 0.9
Note: The regression coefficients (bs) represent the standard deviation difference in the cognitive domain scores as compared with participants with an eGFRcr-cys $ 90 mL/min/1.73 m
2.
Abbreviations: CI, confidence interval; eGFRcr-cys, estimated glomerular filtration rate based on creatinine and cystatin C levels.
aModel 1: unadjusted model; model 2: model 1 1 age, sex, educational level, and glucose metabolism status; model 3: model 2 1 waist circumference, total to high-density lipoprotein
cholesterol ratio, triglyceride level, use of lipid-modifying medication, smoking behavior, and alcohol consumption; model 4: model 3 1 UAE (categorical); model 5a: model 4 1 office systolic
blood pressure, use of antihypertensive medication, prevalent cardiovascular disease, and depression; model 5b: similar to model 5a but adjusted for ambulatory systolic blood pressure instead
of office systolic blood pressure (missing in 343 participants).
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Kidney Function and Cognitive Performancemarkers were not available. In addition, it is important
to note that, for example, blood pressure and CVDmay
also be intermediates in the association between kidney
function and cognitive performance, possibly leading to
underestimation of the evaluated associations.41 How-
ever, the relatively small attenuation of the regression
coefficients after adding these variables suggests that
their role as either confounder or intermediate was
small. Third, individual cognitive tests often incorpo-
rate multiple cognitive domains and their classification
is therefore somewhat arbitrary.42 In addition, although
extensive, the cognitive test battery used did not spe-
cifically assess, for example, working memory, se-
mantic memory, reasoning, and visual-spatial ability.
Fourth, participants with missing data differed from
included participants, and results of the complete case
analyses may be conservative because the additional
multiple imputation analyses also suggested an asso-
ciation between eGFRcr-cys and memory function.
Finally, the absence of direct measurements of GFR
precludes any definitive conclusions on the differences
between the eGFR formulas and their associations with
cognitive decline.
In conclusion, in the entire study population,
albuminuria was independently associated with worse
cognitive performance, in particular within the
domain of information processing speed, whereas
eGFRcr-cys was not associated with cognitive perfor-
mance. However, both albuminuria and eGFRcr-cys
were more strongly and extensively associated with
cognitive performance in older individuals.
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